News: Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

99.49USD
24 May 2013
Price Change (% chg)

$2.75 (+2.84%)
Prev Close
$96.74
Open
$97.93
Day's High
$100.00
Day's Low
$97.73
Volume
176,266
Avg. Vol
112,349
52-wk High
$102.04
52-wk Low
$80.09

Search Stocks
Select another date:

Thu, May 9 2013

BRIEF-Shire wins patent trial against Watson

LONDON, May 9 - Shire PLC : * Shire wins patent trial against watson concerning lialda * Judge confirmed that Shire is entitled to an injunction, which he will issue

Continue Reading

UPDATE 2-Shire cuts sales forecast as drugs miss Q1 targets

* Reduces full-year product forecast to high single-digits

Shire delivers Q1 earnings beat on strong product sales

LONDON, May 2 - British pharmaceutical firm Shire beat expectations with a 10 percent rise in first-quarter earnings on Thursday after a strong performance from its drugs that treat hyperactivity.

Shire settles with Actavis, Watson Pharma on ADHD drug

- Drugmaker Shire Plc said it settled all litigation with Actavis Inc and Watson Pharma, allowing the two companies to sell a generic version of Shire's drug, Intuniv, to treat attention deficit hyperactivity disorder.

Shire settles with Actavis, Watson Pharma on ADHD drug

April 25 - Drugmaker Shire Plc said it settled all litigation with Actavis Inc and Watson Pharma, allowing the two companies to sell a generic version of Shire's drug, Intuniv, to treat attention deficit hyperactivity disorder.

Shire boosts eye business with $160 million SARcode buy

LONDON - Shire is to buy privately owned U.S. biotech firm SARcode Bioscience, paying $160 million upfront to win rights to a new drug in late-stage development for dry eye diseases.

UPDATE 2-Shire boosts eye business with $160 mln SARcode buy

LONDON, March 25 - Shire is to buy privately owned U.S. biotech firm SARcode Bioscience, paying $160 million upfront to win rights to a new drug in late-stage development for dry eye diseases.

UPDATE 1-Shire boosts rare diseases business by buying Premacure

LONDON, March 12 - Shire increased its investment in rare diseases on Tuesday by acquiring privately held Swedish biotech firm Premacure, which is developing a drug for a potentially blinding eye disorder in premature babies.

BRIEF-Shire acquires Premacure AB

LONDON, March 12 - Shire PLC : * Acquires premacure ab * Deal enhances shire's late-stage pipeline with the acquisition of a phase II

UPDATE 1-Shire confident as ADHD competition heats up

* Unworried by FDA approval for Teva's cut-price Adderall XR

Select another date:

Market Views

» More SHPG.OQ Market Views

Press Releases

Search Stocks